Sharing Actual Study Data To Bust Clinical Trial Myths Around DCT

Jane Myles, Curebase's VP of Clinical Trial Innovation, shares the "Evidence of Impact" from a real Curebase study she presented at SCOPE 2022.

Last week, I had the opportunity to attend the SCOPE 2022 conference in Orlando for the first time in two years. Some of the speakers were in-person, some were virtual, some had pre-recorded sessions. I got to reconnect with my mentors and meet new people who inspired me.  SCOPE 2022 was rich with learning opportunities from experts, innovators and solutionists. And, as a bonus, all the live and virtual content is available on-demand  for anyone who registered. I plan to attend some of those sessions from my desk back here in Northern California.

To learn more about Curebase, visit their Clinical Leader page.